[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353729-105":59,"doc-detail-353729-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-alternative-egfr-activation-by-patient-derived-r252c-mutation-promotes-cancer-progression-research-findings-and-therapeutic-implications","An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression - Research findings and therapeutic implications","","An EGFR extracellular-domain mutant, EGFR R252C, was identified in a patient with multifocal lung cancer and glioma, where arginine 252 is replaced by cysteine. The mutation drives disulfide-mediated EGFR dimerization and conformational changes that abolish EGFR autophosphorylation while strengthening direct EGFR–ERK1/2 (extracellular signal-regulated kinase 1/2) coupling. EGFR phosphorylates ERK1/2 at T202/Y204 to activate proliferation and tumor growth in vivo. Afatinib suppresses primary tumor growth and extends progression-free survival, supporting R252C as an actionable activation mechanism and treatment target for lung cancer or glioma.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-alternative-egfr-activation-by-patient-derived-r252c-mutation-promotes-cancer-progression-research-findings-and-therapeutic-implications/353729/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-alternative-egfr-activation-by-patient-derived-r252c-mutation-promotes-cancer-progression-research-findings-and-therapeutic-implications/353729.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the key EGFR mutation studied in this article?","Question",{"text":112,"@type":113},"The study focuses on the patient-derived EGFR R252C mutation, where arginine 252 in the extracellular domain is replaced by cysteine.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does EGFR R252C activate signaling differently from typical EGFR activation?",{"text":117,"@type":113},"EGFR R252C promotes disulfide-mediated EGFR dimerization and conformational change, leading to absent EGFR autophosphorylation but enhanced direct interaction and activation of ERK1/2.",{"name":119,"@type":110,"acceptedAnswer":120},"Does afatinib work against tumors driven by EGFR R252C?",{"text":121,"@type":113},"Yes. Afatinib effectively suppresses primary tumor growth and extends progression-free survival in the patient’s multifocal lung cancer and glioma driven by EGFR R252C.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353729,1790142726,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article [https://doi.org/10.1038/s41467-026-68699-4](https://doi.org/10.1038/s41467-026-68699-4)  \nAn alternative EGFR activation by patientderived R252C mutation promotes cancer progression  \nReceived: 26 March 2025  \n\n| Accepted: 18 December 2025 |\n| --- |\n| |\n| Check for updates |\n\nYajuan Zhang 1,2,10, Qizhen Fei3,10, Yan Li 4,10, Siyao Wang2,10, Tong Rong1,  \nXueyuan Wu5, Hong Gao2, Chen Chen6,7, Dong Gao 2, Yun Zhao 2,  \nGuohui Li 4, Huiying Chu 4 , Wenfeng Li 6  & Weiwei Yang 2,8,9   \nMutations in the extracellular or intracellular domains of epidermal growth factor receptor (EGFR) are implicated in the development of various cancers. While the intracellular mutations of EGFR have been extensively studied, the function of extracellular mutations remains poorly understood. In this study, we identify an EGFR mutant (EGFR R252C) in a patient with multifocal lung cancer and glioma, in which arginine (R) 252 is mutated to cysteine (C) in the EGFR extracellular domain. This mutation promotes C252-C252 disulﬁdemediated EGFR dimerization and induces a conformational change of EGFR, leading to absent autophosphorylation and enhanced direct interaction between EGFR and extracellular signal-regulated protein kinase 1/2 (ERK1/2). Importantly, EGFR directly phosphorylates ERK1/2 at threonine (T) 202 / tyrosine (Y) 204 and activates ERK1/2, thereby promoting tumor cell proliferation and tumor growth in vivo. Afatinib, a second-generation EGFR tyrosine kinase inhibitor, effectively suppresses primary tumor growth and extends progression-free survival in the patient with multifocal lung cancer and glioma driven by EGFR R252C. Our ﬁnding elucidates the activation mechanism of this extracellular EGFR mutation and demonstrates the efﬁcacy of afatinib in treating lung cancer or glioma patients with this variant.  \nEpidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase protein that has been implicated in tumor cell proliferation, angiogenesis, tumor invasion, metastasis, and inhibition of apoptosis. EGFR mutations are observed in approximately 5% of all  \ncancer patients, 14% of non-small cell lung cancer (NSCLC) patients, and 26% of glioma patients1–3. In lung cancer, EGFR mutations predominantly occur in the intracellular kinase domain (KD); these mutations enhance receptor activation by stabilizing the active  \n1Shanghai Institute of Thoracic Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 2Key Laboratory of Multi-cell Systems, Shanghai Key Laboratory of Molecular Andrology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China. 3Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 4Interdisciplinary Research Center for Biology and Chemistry, Liaoning Normal University, Dalian, Liaoning, China. 5Department of Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. 6Department of Radiation Oncology, First Afﬁliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. 7Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, First Afﬁliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China. 8Key Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China. 9Shanghai Academy of Natural Sciences (SANS), Shanghai, China. 10These authors contributed equally: Yajuan Zhang, Qizhen Fei, Yan Li,  \nSiyao Wang. e-mail: [chuhy2009@dicp.ac.cn](chuhy2009@dicp.ac.cn); [liwenfeng@wmu.edu.cn](liwenfeng@wmu.edu.cn); [wyang@sibcb.ac.cn](wyang@sibcb.ac.cn)  \nconformation of the KD, thereby facilitating the dimerization process. While in glioma, EGFR mutatio","cbCaiiFumqO69One","https://ap.wps.com/l/cbCaiiFumqO69One","pdf",2496061,14,"English","# Background and clinical significance\n## EGFR mutations across cancer types\n# Discovery of EGFR R252C and mechanistic findings\n## Disulfide-mediated dimerization and conformational change\n## Loss of autophosphorylation with increased ERK1/2 interaction\n## Direct phosphorylation of ERK1/2 at T202/Y204\n# In vivo tumor effects and therapy response\n## Afatinib efficacy and progression-free survival\n# Implications for treating EGFR extracellular-domain mutations","[{\"question\":\"What is the key EGFR mutation studied in this article?\",\"answer\":\"The study focuses on the patient-derived EGFR R252C mutation, where arginine 252 in the extracellular domain is replaced by cysteine.\"},{\"question\":\"How does EGFR R252C activate signaling differently from typical EGFR activation?\",\"answer\":\"EGFR R252C promotes disulfide-mediated EGFR dimerization and conformational change, leading to absent EGFR autophosphorylation but enhanced direct interaction and activation of ERK1/2.\"},{\"question\":\"Does afatinib work against tumors driven by EGFR R252C?\",\"answer\":\"Yes. Afatinib effectively suppresses primary tumor growth and extends progression-free survival in the patient’s multifocal lung cancer and glioma driven by EGFR R252C.\"}]","An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression - Research findings and therapeutic implications | PDF",1790106981,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97aa7c07d615fd170bd9cb544eacea93.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/181cb11ddffae0a3b6e6e8041d0ce923.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d73c89ff1f1674717de6cfb178799357.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5088843af4dfb296e0eaddef06dfe0ed.webp",980,1301]